# Richard M Nixon

List of Publications by Year
in descending order

| | | | |
|---|---|---|---|
| **34**<br>papers | **1,848**<br>citations | 279798<br>**23**<br>h-index | 377865<br>**34**<br>g-index |
| **34**<br>all docs | **34**<br>docs citations | **34**<br>times ranked | **2994**<br>citing authors |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1 | Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Research and Therapy, 2015, 17, 66. | 3.5 | 175 |
| 2 | Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared. Health Economics (United Kingdom), 2010, 19, 316-333. | 1.7 | 148 |
| 3 | The Effect of Disease, Functional Status, and Relapses on the Utility of People with Multiple Sclerosis in the UK. Value in Health, 2007, 10, 54-60. | 0.3 | 138 |
| 4 | Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Statistics in Medicine, 2007, 26, 1237-1254. | 1.6 | 125 |
| 5 | Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials. Medical Decision Making, 2012, 32, 350-361. | 2.4 | 119 |
| 6 | Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Economics (United Kingdom), 2005, 14, 1217-1229. | 1.7 | 109 |
| 7 | Parametric modelling of cost data: some simulation evidence. Health Economics (United Kingdom), 2005, 14, 421-428. | 1.7 | 84 |
| 8 | Parametric modelling of cost data in medical studies. Statistics in Medicine, 2004, 23, 1311-1331. | 1.6 | 83 |
| 9 | No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing‐Remitting Multiple Sclerosis. Advances in Therapy, 2014, 31, 1134-1154. | 2.9 | 83 |
| 10 | Biologic drugs for rheumatoid arthritis in the medicare program: A cost‐effectiveness analysis. Arthritis and Rheumatism, 2008, 58, 939-946. | 6.7 | 82 |
| 11 | Using multilevel models for assessing the variability of multinational resource use and cost data. Health Economics (United Kingdom), 2005, 14, 185-196. | 1.7 | 69 |
| 12 | How Sensitive Are Cost-Effectiveness Analyses to Choice of Parametric Distributions?. Medical Decision Making, 2005, 25, 416-423. | 2.4 | 65 |
| 13 | Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. International Journal of Clinical Practice, 2009, 63, 766-775. | 1.7 | 61 |
| 14 | Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ: British Medical Journal, 1999, 318, 1246-1250. | 2.3 | 47 |
| 15 | Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population. Value in Health, 2009, 12, 657-665. | 0.3 | 47 |
| 16 | Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials. Medical Decision Making, 2012, 32, 209-220. | 2.4 | 46 |
| 17 | METHODS FOR COVARIATE ADJUSTMENT IN COST‐EFFECTIVENESS ANALYSIS THAT USE CLUSTER RANDOMISED TRIALS. Health Economics (United Kingdom), 2012, 21, 1101-1118. | 1.7 | 44 |
| 18 | Bayesian Hierarchical Models for Cost-Effectiveness Analyses that Use Data from Cluster Randomized Trials. Medical Decision Making, 2010, 30, 163-175. | 2.4 | 42 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 19 | Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study. Journal of Health Economics, 2006, 25, 1015-1028. | 2.7 | 41 |
| 20 | A case study using the PrOACTâ€URL and BRAT frameworks for structured benefit risk assessment. Biometrical Journal, 2016, 58, 8-27. | 1.0 | 34 |
| 21 | Multilevel models for estimating incremental net benefits in multinational studies. Health Economics (United Kingdom), 2007, 16, 815-826. | 1.7 | 29 |
| 22 | The Distribution of the Cost of Multiple Sclerosis in the UK: How Do Costs Vary by Illness Severity?. Value in Health, 2007, 10, 386-389. | 0.3 | 29 |
| 23 | Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension. BMC Medical Research Methodology, 2015, 15, 34. | 3.1 | 29 |
| 24 | Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: An approach to model choice. Statistical Methods in Medical Research, 2016, 25, 2036-2052. | 1.5 | 24 |
| 25 | A comparison of clinical assessment with ultrasound in the management of secondary postpartum haemorrhage. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2002, 104, 113-115. | 1.1 | 17 |
| 26 | The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. Pharmaceutical Statistics, 2009, 8, 371-389. | 1.3 | 16 |
| 27 | High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: meta-analysis and implications. Arthritis Research and Therapy, 2016, 18, 73. | 3.5 | 11 |
| 28 | Evidence That Longer Androgen Receptor Polyglutamine Repeats Are a Causal Factor for Genital Abnormalities. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3207-3210. | 3.6 | 11 |
| 29 | Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies. Scandinavian Journal of Pain, 2017, 16, 74-88. | 1.3 | 10 |
| 30 | Management of menorrhagia: an audit of practices in the Anglia menorrhagia education study. BMJ: British Medical Journal, 2001, 322, 523-524. | 2.3 | 8 |
| 31 | Bayesian evaluation of breast cancer screening using data from two studies. Statistics in Medicine, 2003, 22, 1661-1674. | 1.6 | 8 |
| 32 | Using shortâ€term evidence to predict sixâ€month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. Pharmaceutical Statistics, 2009, 8, 150-162. | 1.3 | 8 |
| 33 | Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint. BMC Medical Research Methodology, 2003, 3, 17. | 3.1 | 3 |
| 34 | Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 793-801. | 1.4 | 3 |